This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n7http://linked.opendata.cz/resource/drugbank/drug/DB08956/identifier/wikipedia/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB08956/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB08956
rdf:type
n3:Drug
n3:description
Hydroxydione (Viadril) is a neuroactive steroid used as a general anesthetic.
n3:generalReferences
# LERMAN LH: Viadril: a new steroid anaesthetic; preliminary communication. Br Med J. 1956 Jul 21;2(4985):129-32. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/13329402
n3:group
withdrawn investigational
owl:sameAs
n10:DB08956
dcterms:title
Hydroxydione
adms:identifier
n6:DB08956 n7:Hydroxydione
n3:salt
n3:synthesisReference
U.S. Patent 2,708,651.
n3:IUPAC-Name
n4:271B5FC5-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5FCB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5FCA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5FC7-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5FC8-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5FC9-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5FC3-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5FC1-363D-11E5-9242-09173F13E4C5 n4:271B5FC4-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5FC2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5FD1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5FD2-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5FCC-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5FCD-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5FCF-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5FCE-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5FD0-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
303-01-5
n3:Bioavailability
n4:271B5FD7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5FD9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5FDA-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5FDB-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5FD6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5FD5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5FD8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5FC6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5FD3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5FD4-363D-11E5-9242-09173F13E4C5